window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM

By |2023-10-04T13:28:49+02:004 October 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for whole-blood

Read More

Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas

By |2023-06-30T09:38:07+02:0030 June 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND –  Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society

Read More

Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs

By |2023-05-15T11:51:50+02:0015 May 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune

Read More

Novigenix announces first closing of its $20M Series B

By |2023-05-15T11:44:51+02:0016 November 2022|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s

Read More

Novigenix gewinnt den Felix Burda Award 2021 in Medizin & Wissenschaft

By |2021-07-23T11:48:23+02:0023 July 2021|Communiqué de presse, News Novigenix|

Kategorie „Innovation in der Immuno-Transkriptomik zur Früherkennung von Darmkrebs"  Auszeichnung würdigt herausragende Innovation und Wirkung bei der Früherkennung von Krebs  LAUSANNE, Schweiz, 22. Juli 2021 /PRNewswire/ -- Novigenix SA, ein führendes Schweizer Biotech-Unternehmen, das immuno-transkriptomische Präzisions-Onkologielösungen entwickelt und vermarktet, gab heute bekannt, dass es mit dem Felix Burda Award 2021 in der Kategorie Medizin

Read More

Colox : an innovation made in Switzerland

By |2017-11-22T12:37:20+02:0015 November 2017|News Novigenix|

Colon cancer kills 5 people every day in Switzerland. "An unacceptable reality", said Brian Haschemi, chairman of Novigenix, a biotech start-up at the heart of the Biopôle in Lausanne. Unacceptable because with early detection, colorectal cancer can be cured. Now the second most deadly form of cancer, the eradication of colorectal cancer represents both a

Read More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Learn more Ok

Privacy Notice

Go to Top